Vertex Pharma Makes A $10 Billion Deal; Crinetics Stock Doubles
Vertex Pharma's $10 billion purchase of Crinetics sparks a near‑doubling of its shares and a biotech‑M&A surge
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Vertex Pharma agreed to acquire Crinetics Pharmaceuticals for $10 billion, a deal highlighted across multiple business outlets. Coverage from Yahoo Finance, Barron's, The Boston Globe and others emphasizes the stock reaction—CRNX shares doubled, reached 52‑week highs, and a reported 99% surge.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (50% supported) Updated 60d ago.
Quick answers
What is the financial size of the Vertex‑Crinetics transaction?
The deal is valued at $10 billion.
How did Crinetics’ stock respond to the announcement?
Crinetics shares doubled, hit 52‑week highs and were reported to have risen 99%.
Which therapeutic areas does the acquisition target?
Coverage cites a strengthening of Vertex’s rare‑disease portfolio and entry into endocrine disease drugs.
Coverage (9)
- Viking Therapeutics (VKTX) Draws Takeover Focus After Vertex's $10 Billion Crinetics Deal Yahoo Finance · 62d ago
- This Biotech Stock Is Soaring 99% After Vertex Agrees to Takeover Deal Barron's · 62d ago
- Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms The Boston Globe · 62d ago
- Why Did CRNX, D, BCRX Stocks Surge To 52-Week Highs Today? Yahoo Finance · 62d ago
- VRTX to Strengthen Rare Disease Portfolio With $10B Crinetics Buyout Yahoo Finance · 62d ago
- Vertex's $10B Crinetics deal marks its clearest step yet toward biopharma's top ranks Endpoints News · 63d ago
- Vertex to acquire Crinetics in $10B foray into endocrine disease drugs BioPharma Dive · 63d ago
- Biggest stock movers Tuesday: CRNX, RIVN, DOCN, and more Seeking Alpha · 63d ago
- Vertex Pharma Makes A $10 Billion Deal; Crinetics Stock Doubles Investor's Business Daily · 63d ago
Topics
Related trends
Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
$160 million ‘moonshot’ backs Boston effort to revolutionize rare disease treatment
A $160 million non-profit initiative in Boston aims to revolutionize the development of genetic medicines for rare and ultra-rare diseases.
Too Much Happiness Sent A Woman To The Emergency Room In an Incredibly Rare Case
A woman was hospitalized after experiencing a rare medical condition triggered by extreme happiness following her daughter's wedding.
Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
AI helped diagnose 18 children whose rare diseases had stumped doctors
An AI model successfully diagnosed rare diseases in 18 children after doctors were stumped.
Lilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’
Eli Lilly reports positive initial Phase 1 clinical data for its $2.3 billion acquisition of Ajax Therapeutics' myelofibrosis treatment.